Rohan Bir Singh1, Shruti Sinha1, Chhavi Saini1, Elsayed Elbasiony1, Sahil Thakur2, Aniruddha Agarwal3. 1. Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear, Boston, MA, 02114, USA. 2. Department of Ocular Epidemiology, Singapore Eye Research Center, Singapore, 169856, Singapore. 3. Advanced Eye Center, Postgraduate Institute of Medical Education and Research, Chandigarh, 160014, India. aniruddha9@gmail.com.
Abstract
PURPOSE: To review the current regimens and novel therapeutic modalities in various stages of research and development for the management of non-infectious posterior uveitis (NIPU). METHODS: We performed a thorough review of current literature using PubMed, Google Scholar and Clinicaltrials.gov to identify the published literature about the available therapeutics and novel drugs/therapies in different stages of clinical trials. RESULTS: The current management regimen for non-infectious posterior uveitis includes corticosteroids, immunomodulatory therapies and anti-metabolites. However, NIPU requires long-term management for efficacious remission of the disease and to prevent disease relapse. Long-term safety issues associated with steroids have led to efforts to develop novel therapeutic agents including biological response modulators and immunosuppressants. The current therapeutic agents in various stages of development include calcineurin inhibitors, biologic response modifiers and a more a comprehensive modalities like ocular gene therapy as well as novel drug delivery mechanisms for higher bioavailability to the target tissues, with minimal systemic effects. CONCLUSION: Novel efficacious therapeutic modalities under development will help overcome the challenges associated with the traditional therapeutic agents.
PURPOSE: To review the current regimens and novel therapeutic modalities in various stages of research and development for the management of non-infectious posterior uveitis (NIPU). METHODS: We performed a thorough review of current literature using PubMed, Google Scholar and Clinicaltrials.gov to identify the published literature about the available therapeutics and novel drugs/therapies in different stages of clinical trials. RESULTS: The current management regimen for non-infectious posterior uveitis includes corticosteroids, immunomodulatory therapies and anti-metabolites. However, NIPU requires long-term management for efficacious remission of the disease and to prevent disease relapse. Long-term safety issues associated with steroids have led to efforts to develop novel therapeutic agents including biological response modulators and immunosuppressants. The current therapeutic agents in various stages of development include calcineurin inhibitors, biologic response modifiers and a more a comprehensive modalities like ocular gene therapy as well as novel drug delivery mechanisms for higher bioavailability to the target tissues, with minimal systemic effects. CONCLUSION: Novel efficacious therapeutic modalities under development will help overcome the challenges associated with the traditional therapeutic agents.
Entities:
Keywords:
Anti-metabolites; Biologics; Interferons; Nanocarriers; Non-infectious uveitis; T cell inhibitors
Authors: Marco Battista; Vincenzo Starace; Maria Vittoria Cicinelli; Luigi Capone; Alessandro Marchese; Giulio Modorati; Francesco Bandello; Elisabetta Miserocchi Journal: Ophthalmol Ther Date: 2021-11-17